Improved survival of systemic sclerosis-associated pulmonary arterial hypertension (SSC-PAH) in the endothelin antagonist era

MH Williams, JG Coghlan(Royal Free London NHS Foundation Trust), Joseph Davar(The Royal Free Hospital), Colette Smith(MRC Clinical Trials Unit at UCL), Akram, CP Denton(The Royal Free Hospital), Clare Das, CE Handler, Casilda G. Black

UCL Discovery (University College London)

May 1, 2005

Cited by 0

Related Papers

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

|Annals of the Rheumatic Diseases|2003|769

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

|Annals of the Rheumatic Diseases|2010|503

The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis

|PLoS Medicine|2018|173

Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium

|The Lancet HIV|2022|140

Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate

|European Neurology|2008|99